Back to homepage

Tag "cardiovascular risk"

Moving from the stratification of primary and secondary prevention of cardiovascular risk in diabetes towards a continuum of risk: need for a new paradigm

Authors: Xavier Garcia-Moll, Vivencio Barrios, Josep Franch-Nadal

This article discusses how patients with diabetes should be treated
according to their CV risk considered as a continuum and not simply as falling within primary or secondary prevention.

More▸

Current perspectives on the use of statins in the treatment of dyslipidaemic patients: focus on pitavastatin

Authors: Lale Tokgözoglu MD, José Luis Zamorano MD

A meeting entitled ‘Current Perspective on the Use of Statins in the Treatment of Dyslipidemic Patients’ was held in Stresa, Italy, on 27–28th June 2019. This meeting report summarizes the main messages of the discussion with a special focus on pitavastatin, whose main features in different settings are described.

More▸

Therapeutic management of hyperlipoproteinemia (a)

Authors: Constantine E Kosmas MD, PhD, Andreas Sourlas, Gordon Mallarkey PhD, Delia Silverio MD, Domingo Y Ynoa MD, Peter D Montan MD, Eliscer Guzman MD, Mario J Garcia MD

This review presents and discusses the current clinical and scientific data pertaining to the therapeutic options for the management of hyperlipoproteinemia (a).

More▸

Impact of lipid-lowering therapy on glycemic control and the risk for new-onset diabetes mellitus

Authors: Constantine E Kosmas MD, PhD, Delia Silverio MD, Andreas Sourlas, Frank Garcia MD, Peter D Montan MD, Eliscer Guzman MD

This review aims to present and discuss the clinical and scientific data pertaining to the impact of lipid-lowering therapy on glycemic control and the risk for new-onset diabetes mellitus.

More▸

Repurposing existing drugs for cardiovascular risk management: a focus on methotrexate

Authors: Arduino A Mangoni MD, PhD, FRCP, FRACP, Sara Tommasi PhD, Angelo Zinellu PhD, Salvatore Sotgia MSc, Ciriaco Carru PhD, Matteo Piga MD, Gian Luca Erre MD

This review discusses the current challenges in the management of cardiovascular disease; the available evidence on the effects of methotrexate on inflammation, blood pressure, and surrogate markers of arterial function; suggestions for future research directions; and practical considerations with the use of methotrexate in this context.

More▸